Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Inovio Pays $5.5 Million For Bioject’s Needle-Free Injection Device Technology



Inovio will pay $5.5 million in cash and company stock for the technology, which it plans to combine with its own skin-surface electroporation DNA vaccine administration technique.

Share this!

March 23, 2016 | by Sarah Massey, M.Sc.

Pennsylvania-based Inovio Pharmaceuticals announced their intention to acquire all needle-free injection devices and intellectual property from Bioject Medical Technologies. Inovio will pay $5.5 million in cash and company stock for the technology, which it plans to combine with its own skin-surface electroporation DNA vaccine administration technique.

Bioject’s ZetaJet delivery system uses an ultra-fine stream of high-pressure fluid to penetrate tiny pores on the skin’s surface, facilitating liquid drug delivery. The company has designed a number of devices for needle-free intramuscular and subcutaneous injections.

According to Inovio, the combination of Bioject’s needle-free injectors and the company’s intracellular delivery using electroporation technology, has resulted in “compelling antigen expression and immune responses in animals.” Inovio plans to apply the combined technologies to their preclinical DNA-based vaccines for Zika, dengue and Respiratory Syncytial Virus (RSV).

“Our current DNA delivery method is highly effective and already gets the job done,” said Dr. J. Joseph Kim, CEO of Inovio. “However, to fully realize the opportunity of mass immunization against challenging infectious diseases we believed we could create an additional advantage: that is non-invasive vaccine administration.

“Similar to our past acquisitions of Advisys and Inovio AS, this purchase of Bioject’s superior jet injection technology and well-positioned patents is an investment in Inovio’s future. Jet injection alone cannot achieve the utility of DNA vaccines. However, combined with our new needle-free skin-surface electroporation delivery technology we believe we can offer a compelling solution to protect against RSV, ever-changing influenza strains, and emerging infectious diseases like Zika.”

The company is also collaborating with AstraZeneca’s MedImmune on its needle-based drug for cervical dysplasia. The drug – which also incorporates electroporation in its delivery – is currently the lead candidate in a Phase II clinical trial.

Inovio has received significant funding from the NIH and the US Army Small Business Innovation Research program to develop the noninvasive DNA vaccine delivery device. The deal between Inovio and Bioject is expected to close in about 30 days.

Keywords: Acquisitions, Vaccine, Drug Delivery


Share this with your colleagues!

Antibiotics Could Be Viable Treatment For Mild Appendicitis

March 22, 2016 - According to researchers at the University of Helsinki, patients with mild appendicitis who were treated with antibiotics do not have a higher risk of developing complications, within one year of starting treatment.

Stem Cells With Half The Normal Number Of Chromosomes To Revolutionize Medical Research

March 21, 2016 - The scientists have successfully generated human embryonic stem cells with just one copy of the 23 human chromosomes.

Cellectis Partners With MabQuest To Develop New Cancer Immunotherapy Antibodies

March 21, 2016 - French biopharmaceutical company Cellectis and Netherlands-based biotech MabQuest, have announced they will be collaborating to develop a novel class of monoclonal antibodies that are antagonistic to a protein called PD-1.


Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub


Development and Manufacture of Highly Potent API Drug Products Throughout the Clinical Phases

Innovation through Integration – Providing Next Generation Biomedical Devices and Interconnects

Clinical Payments Case Studies: Improving Efficiency, Cash Management, and Compliance

Why Phase 3 Trials Fail: Oncology Case Studies and Lessons Learned

Copyright © 2016-2017 Honeycomb Worldwide Inc.